- UroToday Home
- Recent Abstracts
- Urologic Oncology
Renal Cancer
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors.
December 27, 2021
Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma.
December 27, 2021
AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease.
December 24, 2021
Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma.
December 23, 2021
Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
December 23, 2021
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.
December 22, 2021
Multimodal Deep Learning for Prognosis Prediction in Renal Cancer.
December 20, 2021
Prognostic Value of Thyroid Hormone Ratio in Patients With Advanced Metastatic Renal Cell Carcinoma: Results From the Threefour Study (Meet-URO 14).
December 20, 2021
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery
December 17, 2021
Development and Validation of a Predictive Model to Evaluate the Risk of Bone Metastasis in Kidney Cancer.
December 17, 2021
First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series.
December 17, 2021
Prognostic value of CDCA3 in kidney renal papillary cell carcinoma.
December 16, 2021
Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma.
December 16, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
December 15, 2021